The AI revolution may favor incumbents, not just startups. Large companies possess vast, proprietary datasets. If they quickly fine-tune custom LLMs with this data, they can build a formidable competitive moat that an AI startup, starting from scratch, cannot easily replicate.

Xaira's core strategy involves creating massive, proprietary datasets that reveal causal biology. By systematically perturbing every gene in a cell to observe its effects, they generate unique training data for their models, quadrupling the world's supply of such information with a single publication.

The next inflection point will come from clever data generation strategies optimized for AI models, not human analysis. This "black box data" approach—like pooled screening with sequencing readouts—is vastly more scalable and creates a powerful, proprietary moat for companies.

While AI platforms like Anthropic's Claude Science provide a common workbench, true differentiation for biopharma companies comes from the middle layer. This is where proprietary data, custom-built tools, and expert-guided queries create a competitive edge that the commoditized platform itself cannot provide.

InduPro's AI advantage isn't a better algorithm but a superior, proprietary dataset generated in-house. This high-quality data, combining proximity maps with protein quantification, is the true differentiator that their tailor-made AI tools interrogate, avoiding reliance on public data.

A new 'Tech Bio' model inverts traditional biotech by first building a novel, highly structured database designed for AI analysis. Only after this computational foundation is built do they use it to identify therapeutic targets, creating a data-first moat before any lab work begins.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

While public AI models are powerful, they risk becoming commodities when trained on the same public data. Regeneron's strategy is to create a durable advantage by training AI models on its unique dataset of millions of genomes, proteomes, and linked health records to deeply understand human biology.

Moonwalk's discovery engine combines broad, large-scale analysis of public genetic data from millions of individuals with deep, proprietary epigenetic data generated from fat cell samples. This unique data-layering approach allows them to identify novel causal links to obesity that other researchers may have missed.